Teva Pharmaceutical Industries Ltd. (TEVA)

12.56
0.76 6.40
NYSE : Health Technology
Prev Close 11.80
Open 12.51
Day Low/High 12.01 / 12.71
52 Wk Low/High 6.07 / 13.76
Volume 15.62M
Avg Volume 10.87M
Exchange NYSE
Shares Outstanding 1.10B
Market Cap 12.57B
EPS -0.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

I'm Still No Fan of Teva

There continues to be a lot of interest in Teva Pharmaceutical Industries .   Over the last few days I have received a number of inquiries via email.   Here was my most recent analysis of about two weeks ago.    I still would not bottom fish in the ...

Cramer: What's Tax Reform Got to Do With It?

Cramer: What's Tax Reform Got to Do With It?

Treasury secretary says it's baked into the market, but is anyone really counting on it?

Trump Hits Pharma

"Drug companies are getting away with murder." - PresidentTrump   And these words, corralling fears of drug price controls, are taking down Allergan , Teva (which I would sell), big pharma shares and other drug company share prices now.   My sole in...

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise.

3 Biotech Values in a Fully Valued Market

3 Biotech Values in a Fully Valued Market

Eagle Pharmaceuticals, Aratana Therapeutics and Progenics Pharmaceuticals show promise ahead.

Here's Why Teva Isn't My Cup of Tea

On Wednesday I explained why I would avoid Teva Pharmaceutical Industries : I know by the Comments Section that there has been a lot of bottom fishing in Teva (TEVA) . I had done a few hours of research on the company over the last months and passed...

Records for Wall Street, While FDA Approval Pushes Mylan to Top S&P 500

Records for Wall Street, While FDA Approval Pushes Mylan to Top S&P 500

The three major indexes closed at record highs, the Dow for its third day in a row, the Nasdaq its fourth, and the S&P 500 its fifth.

Teva Still Hurts From Self-Inflicted Wounds

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.

Don't Be in a Hurry to Buy Teva Stock

Don't Be in a Hurry to Buy Teva Stock

Trying to catch a falling knife is not a healthy activity.

Teva Should Be Avoided

I know by the Comments Section that there has been alot of bottom fishing in Teva .   I had done a few hours of research on the company over the last months and passed on the name.   I would continue to avoid the shares based, in part, on the follow...

Jim Cramer Reacts to Mylan's Multiple Sclerosis Drug

Jim Cramer Reacts to Mylan's Multiple Sclerosis Drug

Mylan scored FDA approval for a generic version of Teva Pharmaceuticals' multiple sclerosis drug, Copaxone.

Teva Still Hurts From Self-Inflicted Wounds

Teva Still Hurts From Self-Inflicted Wounds

It will take time to turn the drugmaker around under new leadership and it likely is dead money for now.

A Look Back At Teva's History As Mylan Delivers the Drug-Maker Another Blow

A Look Back At Teva's History As Mylan Delivers the Drug-Maker Another Blow

The Israeli pharma company Teva has established a rich history since its founding in 1901. Can it continue to survive as it faces one challenge after another?

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

Mylan Soars After FDA Approval for Generic Copaxone --Biotech Movers

The pharmaceutical company on Oct. 3 said the FDA has approved its generic version of Teva's multiple sclerosis drug Copaxone.

Mylan's Copycat Drug OK Likely to Ding Allergan Shares

Mylan's drug approval announced this morning is a big negative for Teva Pharmaceutical Industries and likely will result in a $3 to $5 drop in Allergan's shares in the early going.

Allergan Makes a Spurt

Allergan is about $5 higher on strength in Teva Pharmaceutical  .   This is about the price at which I reduced late last week to bring the position from large to medium in size.

Recommended Reading

From Barron's online edition today, Teva Pharmaceuticals  could double.

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

S&P 500 and Dow Aim for New Records With Broad-Based Gains Ahead of Fed

Stocks aim for new records with markets in a generally upbeat mood ahead of a decision on interest rates from the Federal Reserve this week.

Will Allergan's Deal With Tribe Hold Up?

Will Allergan's Deal With Tribe Hold Up?

Answering questions from the biotech mailbag.

Teva Pharmaceutical Has a Long Road Back

Teva Pharmaceutical Has a Long Road Back

Damage on TEVA's charts is significant.

How Did Teva Become a Pharmaceutical Giant?

How Did Teva Become a Pharmaceutical Giant?

In August 2016, Teva completed its purchase of Allergan's generic drug business for $33.4 billion in cash and $5.4 billion in stock

Midday Report: Stocks Moving Higher as Weaker Irma Shores Up Optimism

Midday Report: Stocks Moving Higher as Weaker Irma Shores Up Optimism

Stocks rose at midday Monday.

Just What the Doctor Ordered for Allergan

There are two separate and positive developments at Allergan over the last three days that should continue to buoy its shares, which were up $6 on Friday.  First, as I posted over the weekend: Allergan and the Tribe Have Spoken Sep 9, 2017 ' 9:29 AM...

The Makings of Another Huge Rebound?

The Makings of Another Huge Rebound?

Teva could be on the verge of a surge similar to what 3 other companies have seen since 2008-09.

Oversold Small-Cap Biotech Names

Oversold Small-Cap Biotech Names

I am working incrementally into some small stocks with great long-term value.

Closing Bell: Teva Tumbles and Trump Disbands CEO Councils

Closing Bell: Teva Tumbles and Trump Disbands CEO Councils

Domestic politics take the spotlight yet again

Teva Is Cheap, Not Dead

Teva Is Cheap, Not Dead

The drug stock deserved to go down, but the resulting selloff is an overreaction.

Think for Yourself

Think for Yourself

If you want to reap big gains, read, understand and buy when the numbers make sense.

New Trades: Pitney Bowes, Diageo

New Trades: Pitney Bowes, Diageo

A couple of new prospects emerge.